Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)

PHASE2RecruitingINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

April 27, 2021

Primary Completion Date

October 30, 2025

Study Completion Date

January 31, 2026

Conditions
Mild Cognitive ImpairmentAlzheimer Disease
Interventions
DEVICE

Active tPBM-2.0

The NIR continuous wave (average irradiance = 300 mW/cm2) will be used. The duration or irradiation will be for \~11 minutes (666 seconds).

DEVICE

Sham tPBM-2.0

"The sham mode (0 mW/cm2) will be used. The duration or sham irradiation will be for \~11 minutes (666 seconds)."

DRUG

18F-MK-6240

PET tracer to be injected prior to PET imaging session, which will occur during baseline assessments

Trial Locations (3)

10016

RECRUITING

NYU Langone Health, New York

10962

RECRUITING

Nathan Kline Institute, Orangeburg

02114

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

Alzheimer's Association

OTHER

collaborator

LiteCure LLC

INDUSTRY

lead

NYU Langone Health

OTHER